New JAK On The Block: Pacritinib ASCO Data Suggests Edge Against Jakafi
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased platelet counts and reversal of need for blood transfusions in JAK-naïve subset of pivotal PERSIST-1 study suggests pacritinib is modifying disease, not just relieving symptoms, CTI chief exec Bianco says.